RESUMEN
Introducción Los craneofaringiomas son un gran desafío en el campo neuroquirúrgico. Debido a que estas lesiones involucran estructuras importantes, los cirujanos deben sopesar los riesgos de una resección agresiva frente al riesgo de recurrencia a largo plazo. Presentamos los resultados de nuestra serie de pacientes en función de los resultados clínicos, el grado de resección, la recurrencia y la supervivencia libre de enfermedad. Materiales y métodos Se revisaron las historias clínicas de todos los pacientes que se sometieron a una resección quirúrgica por craneofaringioma en el (Hospital Italiano de Buenos Aires) entre 2007 y 2019. Se consideraron exámenes oftalmológicos, estudios de imágenes, estudios endocrinológicos y complicaciones quirúrgicas. En todos los pacientes se planificaron resecciones totales. Para la correcta elección del abordaje quirúrgico, los craneofaringiomas se clasificaron según su ubicación. Resultados Se analizaron treinta pacientes con diagnóstico de craneofaringioma. El 12,5% se clasificó como intraselar, el 12,5% como prequiasmático, el 43,75% como retroquiasmático y el 31,25% como intraventricular. En total, 38 casos incluyeron una cirugía transcraneal (15 abordaje orbitocigomático; 19 abordaje pterional y 4 abordaje transcalloso), siete incluyeron abordaje transeptoesfenoidal, dos abordajes transnasales microscópicos y una endoscopia ventricular para vaciar el quiste del craneofraingioma. La resección total se logró en el 43,7% de los pacientes y la resección casi total (mayor al 90%) en el 25%. El período de seguimiento promedio, después de la resección, fue de 4,7 años. La recurrencia tumoral ocurrió en el 48%, con un promedio de meses libres de enfermedad de 42,7. Conclusión La resección tumoral total es el mejor tratamiento para los craneofaringiomas. Debido a sus altas morbilidad y mortalidad, se necesita un equipo multidisciplinario para el manejo de estos tumores (AU)
Introduction Craniopharyngiomas are a big challenge in the neurosurgical field. Because these lesions involve important systems, surgeons must weigh the risks of aggressive resection against the long-term challenges of recurrence. We present the outcomes of our patients based on clinical results, degree of resection, recurrence and disease-free survival. Materials and methods We reviewed medical records in all patients who had undergone surgical resection for craniopharyngioma at (Hospital Italiano de Buenos Aires) between 2007 and 2019. We considered ophthalmological examinations, imaging studies, endocrinological studies and surgical complications. Radical resections were planned in all of the patients. To help choose the correct surgical approach, craniopharyngiomas were classified based on tumor location. Results Thirty cases of craniopharyngioma were analysed. 12.5% were classified as intrasellar, 12.5% as prechiasmatic, 43.75% as retrochiasmatic, and 31.25% as intraventricular. Overall, 38 cases involved a transcranial surgery (15 orbitozygomatic approach; 19 pterional approach and 4 transcallosal approach), seven involved a transsphenoidal approach, two microscopic transnasal approach and one ventricular endoscopy for emptying the craniopharyngioma cyst. Gross-total resection was achieved in 43.7% and near-total resection (more than 90%) in 25%. The mean follow-up period after resection was 4.7 years. Tumor recurrence occurred in 48%, with an average of 42.7 disease-free months. Conclusion Total tumor resection is the best treatment for craniopharyngioma. Due to its high morbidity and mortality, a multidisciplinary team is necessary for the management of these tumors (AU)
Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Craneofaringioma/diagnóstico por imagen , Craneofaringioma/cirugía , Neoplasias Hipofisarias/diagnóstico por imagen , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias , Estudios Retrospectivos , Resultado del Tratamiento , Recurrencia Local de Neoplasia , Procedimientos NeuroquirúrgicosRESUMEN
INTRODUCTION: Craniopharyngiomas are a big challenge in the neurosurgical field. Because these lesions involve important systems, surgeons must weigh the risks of aggressive resection against the long-term challenges of recurrence. We present the outcomes of our patients based on clinical results, degree of resection, recurrence and disease-free survival. MATERIALS AND METHODS: We reviewed medical records in all patients who had undergone surgical resection for craniopharyngioma at (Hospital Italiano de Buenos Aires) between 2007 and 2019. We considered ophthalmological examinations, imaging studies, endocrinological studies and surgical complications. Radical resections were planned in all of the patients. To help choose the correct surgical approach, craniopharyngiomas were classified based on tumor location. RESULTS: Thirty cases of craniopharyngioma were analysed. 12.5% were classified as intrasellar, 12.5% as prechiasmatic, 43.75% as retrochiasmatic, and 31.25% as intraventricular. Overall, 38 cases involved a transcranial surgery (15 orbitozygomatic approach; 19 pterional approach and 4 transcallosal approach), seven involved a transsphenoidal approach, two microscopic transnasal approach and one ventricular endoscopy for emptying the craniopharyngioma cyst. Gross-total resection was achieved in 43.7% and near-total resection (more than 90%) in 25%. The mean follow-up period after resection was 4.7 years. Tumor recurrence occurred in 48%, with an average of 42.7 disease-free months. CONCLUSION: Total tumor resection is the best treatment for craniopharyngioma. Due to its high morbidity and mortality, a multidisciplinary team is necessary for the management of these tumors.
Asunto(s)
Craneofaringioma , Neoplasias Hipofisarias , Craneofaringioma/diagnóstico por imagen , Craneofaringioma/cirugía , Humanos , Recurrencia Local de Neoplasia/cirugía , Procedimientos Neuroquirúrgicos , Neoplasias Hipofisarias/diagnóstico por imagen , Neoplasias Hipofisarias/cirugía , Complicaciones Posoperatorias , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
Introducción: El papel estimulante de los estrógenos sobre la secreción de prolactina y sobre la proliferación de los lactotropos está bien establecido. Hay escasa literatura sobre los efectos de la menopausia en pacientes con prolactinomas. Objetivos: Evaluar la evolución del tamaño del tumor y de los niveles plasmáticos de prolactina (PRL) en pacientes con microprolactinomas diagnosticados y tratados con agonistas dopaminérgicos (AD) durante su edad fértil y los efectos de la suspensión del tratamiento después de la menopausia. Materiales y métodos: Estudio retrospectivo, multicéntrico. Veintiún pacientes con microprolactinomas diagnosticados durante su edad fértil fueron estudiados en la menopausia. La edad media ± SD de la menopausia fue de 49 ± 3,6 años. En todas las pacientes se suspendió el tratamiento en la menopausia. Resultados: El nivel de PRL pretratamiento fue de 120 ± 58 ng/ml (media±SD) durante la menopausia, al suspender el tratamiento antes de los 12 meses de 23 ± 14 ng/ml y después de 12 meses o más de 1 año de 16 ± 6 ng / ml. Durante la menopausia y al suspender el tratamiento, el tumor desapareció en 9/21 y disminuyó en 12/21 pacientes; un año o más de un año después de la suspensión del tratamiento, el tumor desapareció en 9 /12 y se mantuvo sin cambios en 3/12. La duración promedio del tratamiento fue de 135 ± 74 meses. Dos pacientes reiniciaron el tratamiento debido a que los niveles de PRL aumentaron. Conclusiones: En la mayoría de las pacientes estudiadas se normalizaron los niveles plasmáticos de prolactina y se observó una disminución o desaparición de los microprolactinomas. Los AD podrían suspenderse después de la menopausia en pacientes microprolactinomas. Rev Argent Endocrinol Metab 51:136-141, 2014 Los autores declaran no poseer conflictos de interés.
Introduction: The stimulatory role of estrogens on prolactin secretionn and on proliferation of lactotropic cells is well-established. There is scarce literature about the effects of menopause in patients with prolactinomas. Objectives: To assess the evolution of tumor size and prolactin (PRL) levels in patients with microprolactinomas diagnosed and treated with dopamine agonists bromocriptine (BEC)/cabergoline (CAB) during their fertile age and the effects of discontinuation of those drugs after menopause. Material and methods: retrospective, multicenter study. Twenty-one patients diagnosed with microprolactinomas during their fertile age were studied in their menopause. Mean ± SD age at menopause was 49±3.6 years. In all patients, treatment was stopped when they reached menopause. Results: Mean ± SD pre-treatment PRL level was 120 ± 58 ng/ml and during menopause after stopping treatment, it was 23 ± 14 ng/ml before 12 months, and 16 ± 6 ng/ml after 12 months. During menopause and when stopping treatment, the tumor disappeared in 9/21 and the tumor size decreased in 12/21 patients; a year or more after treatment discontinuation, the tumor disappeared in 9/12 and was unchanged in 3/12. The mean ± SD treatment duration was 135 ± 74 months. Two patients were restarted on treatment because PRL levels increased. Conclusions: Normal PRL levels and sustained reduction or resolution of adenomas were achieved in most patients studied. Only two out of 21 restarted treatment because of hyperprolactinemia. Dopamine agonists might be safely stopped after menopause in patients with microprolactinomas. Rev Argent Endocrinol Metab 51:136-141, 2014 No financial conflicts of interest exist.
RESUMEN
The term primary empty sella (PES) makes reference to the herniation of the subarachnoid space within the sella turcica in patients with no history of pituitary tumor, surgery or radiotherapy. To retrospectively assess clinical features, radiological findings and the biochemical endocrine function from the records of 175 patients with a diagnosis of PES. One hundred seventy-five patients (150 females) were studied. The mean age at diagnosis was 48.2 ± 14 year. Most diagnoses were made by magnetic resonance imaging (n = 172). In most patients, the pituitary function was assessed by basal pituitary hormones measurements. Pituitary scans were ordered for different reasons: headache (33.1 %), endocrine disorders (30.6 %), neurological symptoms (12.5 %), visual disturbances (8.75 %), abnormalities on sella turcica radiograph (8.75 %) and others (6.25 %). Multiple pregnancies were observed in 58.3 % of women; headaches, obesity, and hypertension were found in 59.4, 49.5, and 27.3 % of the studied population, respectively. Mild hyperprolactinemia (<50 ng/ml) was present in 11.6 % of women and 17.3 % of men. Twenty-eight percent of our patients had some degree of hypopituitarism. In the male population, hypopituitarism represented 64 % of cases, whereas it accounted for 22 % of all females. PES seems to be more commonly found in middle-aged women, with a history of multiple pregnancies. In most patients, PES was discovered as an incidental finding on imaging studies, while in almost a quarter of patients PES was found during the diagnostic evaluation of anterior pituitary deficiency, which was more common in men.
Asunto(s)
Síndrome de Silla Turca Vacía/patología , Adulto , Síndrome de Silla Turca Vacía/diagnóstico por imagen , Femenino , Humanos , Hiperprolactinemia , Hipopituitarismo/diagnóstico por imagen , Hipopituitarismo/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Radiografía , Estudios Retrospectivos , Silla Turca/diagnóstico por imagen , Silla Turca/patologíaRESUMEN
Introducción: El término Silla Turca Vacía Primaria (STVP) hace referencia a la invaginación del espacio subaracnoideo hacia el interior de la silla turca en pacientes sin antecedentes de tumor, cirugía o radioterapia de la región selar. Aunque usualmente no está asociado con disfunciones endocrinas, diferentes grados de hipopituitarismo e hiperprolactinemia han sido reportados. Objetivo: Analizar retrospectivamente datos clínicos, hallazgos radiológicos y bioquímicos de 117 pacientes con diagnóstico de STVP. Pacientes y Métodos: Se estudiaron 117 pacientes, 98 mujeres (48 ± 14.9 años). Los diagnósticos fueron realizados por Resonancia Magnética Nuclear (n=115) y Tomografía Computada (n=2). La evaluación de la función adenohipofisaria se realizó a través de determinaciones hormonales basales. Resultados: Los motivos que llevaron al pedido de las imágenes fueron: cefaleas (35 %), sospecha clínica y/o bioquímica de deficiencia pituitaria (22 %), trastornos visuales (11 %), anormalidades de la radiografía simple de la silla turca (11 %), hiperprolactinemia (2,6 %), otros (18.4 %). El 48,9 % de las mujeres eran multíparas. Cefaleas, obesidad, hipertensión arterial y autoinmunidad tiroidea fueron halladas en el 60, 67, 24,5 y 22,5 % de la población evaluada respectivamente. Hiperprolactinemia (< 50 ng/ml) estuvo presente en 6,1 % de las mujeres y 15, 8 % de los hombres. El 27 % de los pacientes estudiados presentó algún grado de hipopituitarismo, que fue más frecuente en la población masculina. Conclusiones: STVP fue más frecuente en mujeres multíparas de mediana edad. En la mayoría de los casos fue descubierta incidentalmente por estudios radiológicos, mientras que en un cuarto de los pacientes, fue encontrada durante la evaluación diagnóstica de deficiencia adenohipofisaria, lo cual fue más frecuente en hombres.
Introduction: The term Primary Empty Sella (PES) makes reference to the herniation of the subarachnoid space within the sella turcica in those patients with no history of pituitary tumor, neither surgery, nor radiotherapy. Though it is usually not associated with endocrine abnormalities, different degrees of hypopituitarism and mild hyperprolactinemia have been reported. Objective: To assess clinical features, radiological findings and biochemical endocrine function retrospectively from the records of 117 patients with diagnosis of PES. Patients and Methods: One hundred seventeen patients, 98 females, were studied. The mean age at diagnosis was 48 ± 14.9 yr. Most diagnoses were made with magnetic resonance imaging (n = 115), and only 2 through sellar computed tomography scan. Only pituitary basal hormones determinations were made, except for the TRH and ACTH tests which were performed for the diagnosis of primary hypothyroidism and secondary adrenal failure respectively. Results: Pituitary images were requested because of different reasons: headaches (35 %), clinical and biochemical suspicion of pituitary deficiency (22 %), visual disturbances (11 %), abnormalities on the simple sella turcica radiography (11 %) hyperprolactinemia (2.6 %), others (18.4 %): dizziness, seizures, rhinorrhea, loss of consciousness, skull trauma, galactorrhea. Multiple pregnancies were observed in 48.9 % of women; headaches, obesity, arterial hypertension and thyroid autoimmunity were found in 60 %, 67 %, 24.5 % and 22.5 % of the studied population respectively. Mild hyperprolactinemia (< 50 ng/ml) was present in 6.1 % of women and 15.8 % of men. Twenty seven percent of our patients had some degree of hypopituitarism. For male population hypopituitarism comprised 72 %, whereas it took up 19 % for the whole female group. Conclusions: PES seems to be more commonly found in middle-aged women (sex ratio 5/1) with history of multiple pregnancies. In most patients it was discovered as an incidental finding at image studies, while in almost a quarter of patients PES was found during the diagnosis stage of anterior pituitary deficiency, which was more frequently seen among men.
RESUMEN
Introducción: La determinación de IGF-I en suero o plasma es una herramienta esencial en el diagnóstico y seguimiento de la acromegalia. Sin embargo, se deben tener presentes algunos inconvenientes en su medición por diferentes inmunoensayos. Objetivos: Evaluar dos inmunoensayos para la determinación de IGF-I y su correlación con el nadir de GH en el TTOG en pacientes acromegalicos. Materiales y métodos: Se analizaron 37 pacientes acromegálicos, 20 mujeres y 17 hombres. IGF-I fue determinada por Immulite 1000, (IMM) y por IRMA (DSL). Se realizó el TTOG y se determinó glucosa y GH en todos los tiempos (basal, 30, 60, 90 y 120min). Se consideró respuesta normal un nadir de GH <1ng/ml. Nueve pacientes se encontraban bajo tratamiento y 28 sin tratamiento. Análisis estadístico: se utilizaron el test de Wilcoxon, de Bland y Altman y curvas ROC. Se consideró significativa una p<0,05. Resultados: Las concentraciones basales de glucosa fueron 97,86±10,91 mg/dl, de GH 2,8 (1,59-14,4) ng/ml, de IGF-I por IMM 602±318 ng/ml y por DSL 1006±596 ng/ml. IGF-I por IMM y DSL mostró una diferencia significativa con p <0,01 y un bias de - 403,2 ng/ml con valores menores por IMM. IGF-I elevada por IMM y DSL, se encontró en el 84% y en el 97% respectivamente. IGF-I elevada con nadir de GH >1ng/ml se encontró en el 70%, con nadir de GH normal en el 13,5%. IGF-I normal con nadir >1ng/ml en el 2,7% y con nadir de GH normal en el 13,5%. El área bajo las curvas ROC no mostró diferencias significativas. Conclusiones: Los niveles de IGF-I determinados por IMM y DSL fueron significativamente diferentes mostrando un bias negativo para IMM. La mayoría de los valores del nadir de GH fueron consistentes con los niveles de IGF-I observándose una discrepancia en el 30% de los pacientes, estuvieran o no bajo tratamiento.
Introduction: IGF-I determination in serum or plasma is an essential tool in the diagnosis and follow-up of acromegaly. Hepatic production of IGF-I is regulated by GH and circulates bound to several IGF-I binding proteins which extends its half life. IGF-I is not released in a pulsatile pattern and has no significant variability in 24 h. Objective: To evaluate two different methodologies in IGF-I levels determination and their correlation with GH nadir in OGTT in acromegalic patients. Material and methods: We analyzed 37 acromegalic patients, 20 women and 17 men, mean age was 45±12 years. IGF-I levels were assayed by Immulite 1000, DPC (IMM) and DSL-5600 ACTIVE® IGF-I Coated-Tube IRMA (DSL) and OGTTs (at baseline and at 30, 60, 90 and 120 minutes) were performed by measuring plasma glucose and GH assay by immunochemiluminometric assay (Access); we considered a nadir <1ng/ml as normal response. Nine patients were under medical treatment (cabergoline: 4, octeotride: 4, and cabergoline plus octeotrite: 1) and 28 without treatment. Statistical analysis: Wilcoxon and, Bland and Altman tests and ROC curves. Differences were considered significant at p< 0.05. Results: Basal glucose levels were 97.86±10.91 mg/dl and mean GH was 2.8 (1.59-14.4) ng/ml. Mean IGF-I levels performed by IMM were 602±318 ng/ml and 1006±596 ng/ml by DSL. There was a statistically significant difference between both methodologies (p<0.01). Bland and Altman test showed a bias of - 403.2 ng/ml with lower values by IMM. We observed elevated IGF-I levels in 84% by IMM and in 97% by DSL, and only one patient had normal levels with both methodologies. Elevated IGF-I levels and GH nadir >1ng/ml were observed in 70% of the patients, increased IGF-I with normal GH nadir in 13.5%, normal IGF-I with GH nadir >1ng/ml in 2.7% and normal IGF-I with normal GH nadir in 13.5%. Patients under treatment: 3 showed normal GH nadir with elevated IGF-I levels, in 2 of them by both methodologies, and in the other one it was normal by IMM and elevated by DSL; the other 6 showed GH nadir > 1ng/ml, 5 of them presented elevated IGF-I by both methodologies and the other one showed discrepancy in IGF-I levels. The under ROC curve area and confidence interval (CI) of 95% for IGF-I IMM and DSL were 0.96 (0.90-1.00) and 0.91 (0.82-1.00) respectively. Differences between the ROC curves areas were not significant Conclusions: IGF-I levels determined by IMM and DSL were statistically significantly different. IGF-I levels showed a negative bias by IMM. Most of the results of GH nadir were consistent with IGF-I levels but we observed discrepancy in 30% of the patients, regardless of whether they were under treatment or not.
Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Acromegalia/sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Prueba de Tolerancia a la Glucosa/estadística & datos numéricos , Inmunoensayo/métodos , Interpretación Estadística de Datos , Hormona de Crecimiento Humana/análisisRESUMEN
Objetivos: Estimar la frecuencia de complicaciones maternofetales en mujeres que se embarazaron durante el tratamiento con cabergolina (CAB). Estimar la frecuencia de patología detectada posnacimiento en los niños producto de dichos embarazos. Material y métodos: Estudio retrospectivo y multicéntrico de 86 embarazos en 78 mujeres con hiperprolactinemia idiopática (7) o tumoral (44 micro y 27 macro), en tratamiento con CAB en el momento de la concepción. Edad: 20 a 45 años; PRL inicial: 30 a 1429 ng/ml; duración del tratamiento previo al embarazo 1 a 120 meses; dosis: 0.125 a 4 mg/semana. El rango de exposición embriofetal a la CAB fue de 3 a 27 semanas, el 96.39% de las pacientes la recibió durante el primer trimestre y el 3.61% hasta el segundo. Resultados: No hubo complicaciones mayores durante el embarazo. Se registraron 7 abortos espontáneos (8.1%) y 75 partos, de los cuales 49 fueron vaginales y 26 cesáreas. Se registraron 69 recién nacidos, 63 fueron a término y 6 pretérmino (8.8%), ninguno bajo peso para la edad gestacional. En 3 (5.2%) recién nacidos se observó: 1 malformación mayor (Síndrome de Down) y 2 menores (hernia umbilical e inguinal). Se obtuvo seguimiento de 42 recién nacidos; se diagnosticó epilepsia refractaria en uno y un trastorno generalizado del desarrollo en otro. No se halló una mayor frecuencia de complicaciones en los embarazos ni en los recién nacidos expuestos a CAB que en la población normal. Sería necesario mayor número de pacientes para concluir sobre la seguridad de CAB durante el embarazo.
Objectives: To assess the rate of any potential adverse effects on pregnancy and embryo-fetal development in women who became pregnant under treatment with cabergoline (CAB). To follow up medical data of children who were born from mothers exposed to Cab in early weeks of gestation. Material and methods: Observational, retrospective and multicenter study on 86 pregnancies in 78 women with idiopathic or tumoral hyperprolactinemia. All patients were under Cab at conception. The average age was 29 (range: 20-45). Pituitary images at diagnosis showed 44 microadenomas, 27 macroadenomas and 7 were normal. Serum PRL at baseline was between 30 and 1429 ng/ml. Duration of therapy before pregnancy ranged from 1 to 120 months. Maternal and fetal exposure to cabergoline and doses ranged from 0.125 to 4 mg/week. The mean serum PRL level under which patients achieved pregnancy was 17 ng/ml. Fetal exposure ranged from 3 to 27 weeks; 96.39% of patients received CAB during the first trimester of pregnancy and 3.61% until the second one. Results: No significant complications during pregnancy were found. Seven women (8.1%) had spontaneous abortions. Term deliveries were recorded in 63/69, preterm in six (8.8%), none of them with low weight for gestational age. Neonatal abnormalities were observed in 3 (5.2%): 1 major (Down syndrome) and 2 minor malformations (umbilical and inguinal hernia). Two out of 42, developed abnormalities during the follow- up, one of them was a refractory epilepsy during the second month of life, the other presented a Pervasive Developmental Disorder diagnosed in the third year of life. Conclusion: No significantly higher frequency of complications was found in pregnancies and/or offspring exposed to CAB than in normal population. Larger series of patients are needed to asses the safety.
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Persona de Mediana Edad , Complicaciones del Embarazo/etiología , Ergolinas/efectos adversos , Anomalías Congénitas/prevención & control , Embarazo/efectos de los fármacos , Desarrollo Embrionario y Fetal/efectos de los fármacosRESUMEN
Objetivo: Analizar la presentación clínica, radiológica, bioquímica y el comportamiento posquirúrgico de una cohorte de pacientes portadores de gonadotrofinomas. Pacientes y Métodos: Se evaluaron pacientes con gonadotrofinomas estudiados en nueve centros endocrinológicos de la ciudad de Bs.As. durante el período 1983 a 2003. El criterio de inclusión fue la inmunohistoquímica (IH) positiva para hormona luteinizante (LH), folículoestimulante (FSH) y/o alfa subunidad (ASU). Los adenomas plurihormonales fueron excluidos. Resultados: Fueron analizados 66 pacientes de 51,8 ± 12,1 (X +/- DS) años (39 varones). Los síntomas mas frecuentemente observados fueron las alteraciones visuales (72,8%), seguidas por el hipogonadismo y las cefaleas. El 10,6% se diagnosticaron en forma incidental. El 98,5% fueron macroadenomas, 56,9% de los cuales correspondieron a un estadio Hardy (EH) 3 y 29,6% a un EH 4. El tiempo de seguimiento fue de 47,8 meses (r: 5-168). El hipogonadismo definido bioquímicamente se presentó en el 82,4% de los pacientes. En su mayoría presentaban niveles bajos o inapropiadamente normales de gonadotrofinas, pero 4 mujeres y 3 varones presentaron niveles séricos elevados y disociados de FSH y LH. La hiperprolactinemia por desconexión fue observada en 45,2% de la población (X: 65.6 ng/ml r: 30-172). El hipopituitarismo se detectó en 25,7% de los casos. La cirugía fue transeptoesfenoidal (TSE) en 80%; una segunda operación fue realizada en el 28% de la población. La IH fue positiva por orden de frecuencia para LH, FSH y ASU o las 3 combinaciones. La evolución posquirúrgica evidenció mejoría en el campo visual (CV) en el 41%. La presencia de restos tumorales y/o recidiva fue del 84%. Se indicó radioterapia en 37% y la sustitución hormonal fue necesaria en el 65% de los pacientes.
The aim of our study was to describe the clinical-biochemical and radiologic presentation and the post surgery outcome in a cohort of patients with gonadotrophinomas. Patients were selected from nine Endocrinology Units of the city of Buenos Aires from 1983 at 2003. The inclusion criteria was defined by nonfunctinoning pituitary adenomas with positive innmunohistochemical (IH) for luteinizing hormone (LH), follicle-stimulating hormone (FSH) and/or alpha subunit (ASU). Innmunohistochemically plurihormonal adenomas were excluded. Sixty six patients were analyzed, aged 51,8 ± 12,1 (X +/- DS) years; (39 men). More prevalent symptoms were visual alterations (72,8%), hypogonadism and headaches. Eleven percent was diagnosed as incidentalomas. Ninety eight percent were macroadenomas, 56,9% was Hardy stage (HS) 3 and 29,6% was HS 4. The patients were followed up for 47,8 months (r: 5-168). Hypogonadism was biochemically found in 82,4%. The majority showed low or inappropriately normal levels of gonadotrophins except for 4 women and 3 men that had high and dissociated levels. Hyperprolactinemia was observed in 45,2% and was interpreted as an interference with normal dopamine inhibition of prolactin secretion (X+/-DS: 65.6+/- ng/ml, r: 30-172). Hypopituitarism was found in 25,7% of the patients. Transsphenoidal surgery was carried out in 80% and in 28% a second surgery was needed. The IH was positive for LH, FSH and ASU in this order of frequency or its combinations. Tumor persistency and/or recurrency were found in 84% of the patients. Forty one percent showed improvement of visual defects. Radiotherapy was indicated in 37% and hormonal replacement was needed in 65% of the patients.
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Adenoma Cromófobo/sangre , Adenoma Cromófobo/diagnóstico por imagen , Neoplasias Hipofisarias/etiología , Adenoma Cromófobo/cirugía , Estudios Retrospectivos , Gonadotropinas Hipofisarias/inmunologíaRESUMEN
The aim of this study was to assess the GH-IGFI axis, GH receptor availability, as reflected by the levels of GH-BP, and the amount of GH-dependent IGFBP-3 in adult IDDM patients with different degrees of metabolic control. Thus, 10 adult well-controlled IDDMs (HbA1 7.8 +/- 0.4%), 10 adult non-ketotic poorly controlled IDDMs (HbA1 13.3 +/- 7%) and 14 sex- and age-matched healthy controls were subjected to two intravenous GH-RH stimulation tests with 0.1 and 1.0 microg/kg body weight respectively, and a plasma IGF-1 generation test induced by the administration of hGH. Poorly controlled IDDM patients exhibited an exaggerated GH response to 1.0 microg/kg of GH-RH when compared to healthy control subjects. Low fasting plasma IGF-1 levels and a blunted IGF-1 response to exogenously administered hGH were also found in poorly controlled IDDMs when compared to the healthy control group. GH-BP levels were significantly lower in IDDMs than in normal controls, and correlated positively with the IGF-1 generation capacity after hGH. Serum IGFBP-3 levels measured by RIA were similar in IDDM and control groups. Good glycemic control for 5.7 +/- 0.9 months did not correct the above mentioned abnormalities of the GH-IGF-1 axis. Our findings suggest that IDDM is associated with a diminished availability of GH receptors and synthesis of IGF-1. GH might then increase as a compensatory mechanism, further down-regulating liver GH receptors, and thus perpetuating the initial abnormality.
Asunto(s)
Diabetes Mellitus Tipo 1/fisiopatología , Resistencia a Medicamentos , Hormona Liberadora de Hormona del Crecimiento/farmacología , Hormona de Crecimiento Humana/sangre , Hormona de Crecimiento Humana/farmacología , Factor I del Crecimiento Similar a la Insulina/metabolismo , Adulto , Glucemia/metabolismo , Proteínas Portadoras/sangre , Femenino , Humanos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Masculino , Receptores de Somatotropina/metabolismoRESUMEN
UNLABELLED: The hypothalamic-pituitary insulin-like growth factor I (IGF-I) axis was evaluated in 12 children with chronic renal failure (CRF) aged 3.2 to 16.5 yr (mean 9.5) on chronic dialysis, and in 13 renal transplantation patients aged 7.5 to 15.0 yr (mean 11.1). Height standard deviation score (SDS) was -2.8 +/- 0.5 (mean +/- SE) and -3.0 +/- 0.3 SDS (p = NS), and growth velocity was 3.7 +/- 0.4 and 1.5 +/- 0.3 cm/year (p < 0.01), respectively. Mean nocturnal growth hormone (mean GH) and number of pulses > 5 ng/ml in CRF and transplantation children were 4.2 +/- 0.8 vs 2.4 +/- 0.3 ng/ml, p = 0.08 and 1.7 +/- 0.2 vs 1.0 +/- 0.2, p < 0.05, respectively. In transplant children there was a positive correlation between mean GH and growth velocity (p < 0.02). GH peak response and the area under the curve post GH releasing hormone test were significantly higher in CRF and transplant children treated with deflazacort (new steroid derived from prednisolone) vs transplant children treated with methylprednisone. Mean serum IGF-I levels were -0.5 +/- 0.2 SDS for chronological age (CA) in CRF patients and +0.8 +/- 0.2 SDS(CA) in transplant patients, p = NS. In the latter, serum IGF-I values were positively correlated with growth velocity (p < 0.02) and negatively correlated with methylprednisone dose (p < 0.05). CONCLUSIONS: Patients with CRF and growth retardation have a higher number of GH peaks and slightly elevated mean GH levels compared to transplant patients. After renal transplantation GH secretion may be influenced by glucocorticoids as shown by the lower GH response to GHRH which improved with deflazacort and the inverse correlation between methylprednisone dose and IGF-I levels.
Asunto(s)
Hormona de Crecimiento Humana/sangre , Factor I del Crecimiento Similar a la Insulina/metabolismo , Fallo Renal Crónico/fisiopatología , Adolescente , Adulto , Estatura , Niño , Ritmo Circadiano , Femenino , Hormona Liberadora de Hormona del Crecimiento , Humanos , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Masculino , PeriodicidadRESUMEN
The aim of the present investigation was to study normal rats fed a sucrose-rich diet (SRD) for a prolonged period (up to 30 weeks) (1) to obtain additional data on the hormonal and metabolic patterns induced by this treatment and (2) to provide information on changes taking place in the pancreatic islet cell populations. We found that long-term feeding with a SRD resulted in a steady state of hypertriglyceridemia and hyperglycemia in which insulin levels remained unchanged and unable to compensate for the increased demands of the developing metabolic changes. The endocrine pancreas showed a significant increase of both islet number and B-cell area, as well as changes in the profile of islet cell distribution. However, these changes were not accompanied by an increase in the pancreatic content of immunoreactive insulin (IRI). It may therefore be postulated that the newly emerged B-cell mass has some sort of derangement with the increased insulin demand resulting from insulin resistance induced by the long-term SRD feeding. Thus, feeding a SRD to normal rats may prove to be an attractive animal model for studying the role of environmental nutritional factors in the unsettled issue of the relationship between insulin resistance and relative insulin deficiency. The model might provide key information for understanding the pathophysiology of human diseases such as type II diabetes, dyslipidemia, and a number of entities included in so-called syndrome X.
Asunto(s)
Islotes Pancreáticos/metabolismo , Sacarosa/administración & dosificación , Animales , Peso Corporal , Conducta Alimentaria , Prueba de Tolerancia a la Glucosa , Inmunohistoquímica , Insulina/metabolismo , Islotes Pancreáticos/anatomía & histología , Masculino , Ratas , Ratas WistarRESUMEN
Objetivos: Investigar la asociación entre los niveles de GH - IGF-I -IGFBP-3 y progesterona (Pg) en líquido folicular humano y el nº de ovocitos reclutados, su madurez, fertilización y clivaje in vitro. Material y Métodos: Diseño: Observacional, analítico transversal. Se estudió el fluido folicular de 74 folículos, cada uno conteniendo un ovocito, en 17 pacientes, luego de su aspiración para FIV-ET, registrándose para cada ovocito su clasificación y evolución en cultivo. Se midieron los niveles de GH, IGF-I, IGFBP-3 y Pg por RIA. Los valores se expresan en Md (rango intercuartílico). Resultados: El grupo de pacientes de baja respuesta folicular (ovocitos < ó=3) presentó menores niveles intrafoliculares de GH y Pg que las normorespondedoras. [0,7 (0,34) vs 1,25 (0,87) ng/ml, p < 0,01; 6.775,1 (4.225,5) vs 10.180,0 (6.700,5) p < 0,01, respectivamente]. Las concentraciones intrafoliculares de GH e IGF-I fueron significativamente mayores en el grupo que recibió análogos GnRH [1,26 (1,12) vs 0,56 (0,74) ng/ml, p < 0,002 y 0,62 (0,3) vs 0,42 (0,34) U/ml, p < 0,03]. La fertilización ovocitaria y clivaje positivos se asociaron a mayores concentraciones de GH [1,26-(1,1) vs 0,56 (0,98) ng/ml, p < 0,02], IGF-1 [0,63 (0,28) vs 0,51 (0,3), p < 0,05] e IGFBP-3 [2,8 (1,4) vs 1,89 (1:91) p < 0,01]. Conclusiones: Los resultados observados sugieren: 1) Existiría una asociación entre la baja respuesta ovocitaria y menores concentraciones intrafoliculares de GH y Pg. 2) La administración de análogos modularía positivamente el sistema GH - IGF-I durante la foliculogenesis. 3) A su vez la exposición a mayores niveles de GH e IGF-I se vincularía a una myor habilidad del ovocito para fertilizar y clivar in vitro
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Fertilización In Vitro , Hormona del Crecimiento/uso terapéutico , Factor I del Crecimiento Similar a la Insulina , Goserelina/uso terapéutico , Líquido Folicular , Líquido Folicular/química , Oocitos/efectos de los fármacos , ProgesteronaRESUMEN
Objetivos: Investigar la asociación entre los niveles de GH - IGF-I -IGFBP-3 y progesterona (Pg) en líquido folicular humano y el nº de ovocitos reclutados, su madurez, fertilización y clivaje in vitro. Material y Métodos: Diseño: Observacional, analítico transversal. Se estudió el fluido folicular de 74 folículos, cada uno conteniendo un ovocito, en 17 pacientes, luego de su aspiraci
Asunto(s)
Humanos , Femenino , Embarazo , Adulto , Hormona del Crecimiento/uso terapéutico , Factor I del Crecimiento Similar a la Insulina/diagnóstico , Fertilización In Vitro/efectos de los fármacos , Oocitos/efectos de los fármacos , Progesterona/diagnóstico , Goserelina/uso terapéutico , Líquido Folicular/efectos de los fármacos , Líquido Folicular/químicaRESUMEN
Patients with a successful renal transplant may have abnormalities in thyroid function. We evaluated serum thyroid hormone levels, serum thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH), and the circadian pattern of serum TSH in 18 children aged 6.6-19.4 years (median 12.6 years), 4.0 +/- 2.9 years after renal transplantation. In 14 children, immunosuppressive therapy included methylprednisone [mean (+/-SD) 0.17 +/- 0.05 mg/ kg per day], while in 11 it included deflazacort (0.32 +/- 0.1 mg/kg per day). Seven children were studied twice, under methylprednisone and again while on deflazacort therapy. Mean total and free thyroxine (T4) values were significantly below the mean control levels (total T4 108.5 +/- 21.5 vs. 118.7 +/- 22.1 nmol/l, P < 0.05 and free T4 14.4 +/- 4.0 vs. 18 +/- 4.9 pmol/l, P < 0.001). Morning basal TSH levels were within the normal range. The mean TSH increment after TRH was 4.4 +/- 3.5 mU/l, significantly lower than that of controls (10.8 +/- 4.26, P < 0.001). Of 7 patients on methylprednisone, 4 had nocturnal TSH surges below the normal range (95% confidence limits 47%-300%); this occurred in 3 of 8 patients on deflazacort therapy. The TSH response to TRH was correlated with deflazacort dose. Patients on methylprednisone and deflazacort therapy had similar thyroid alterations. Our findings support the hypothesis that after renal transplantation some children have hypothalamic-pituitary thyroid abnormalities in which glucocorticoids may play a significant role.
Asunto(s)
Sistema Hipotálamo-Hipofisario/fisiopatología , Trasplante de Riñón/efectos adversos , Glándula Tiroides/fisiopatología , Adolescente , Adulto , Niño , Femenino , Humanos , Masculino , Hormonas Tiroideas/sangre , Tirotropina/sangre , Hormona Liberadora de Tirotropina/farmacologíaRESUMEN
Growth retardation is a prominent clinical manifestation in children with chronic renal failure (CRF). Nine children with CRF (3 on conservative treatment; 3 on dialysis and 3 after renal transplantation) aged 1.6 to 14.0 (x +/- SE: 8.1 +/- 1.4) years, were treated with twice daily subcutaneous injections of 26 +/- 2.4 micrograms/kg/day growth-hormone-releasing-hormone [GHRH (1-29) NH2 Serono (Geref)] during 3 to 6 months. Mean serum urea and creatinine remained stable, although 2 patients on conservative treatment showed a moderate increase in serum creatinine. At the start of the study, height SDS was -2.2 +/- 0.2 (x +/- SE), growth velocity was 4.5 +/- 1.0 cm/year (-2.3 +/- 0.6 DS for chronological age) and growth hormone (GH) response to acute GHRH test (1 microgram/kg IV) was 62 +/- 17.5 ng/ml. Five patients increased height velocity from 3.8 +/- 0.7 to 8.0 +/- 1.2 cm/year (paired t test, p < 0.05). The peak GH response to GHRH was significantly higher in the group of growth non-responders than in the responders (p < 0.05). In conclusion, 5 out of 9 short children with CRF, 3 on conservative treatment, 1 on dialysis and 1 post renal transplantation, showed improved growth in response to GHRH therapy. No consistent effect on renal function was detected. GHRH may be an alternative therapy to increase growth velocity in patients with CRF.
Asunto(s)
Crecimiento/efectos de los fármacos , Fallo Renal Crónico/tratamiento farmacológico , Sermorelina/farmacología , Adolescente , Antropometría , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Sermorelina/uso terapéuticoRESUMEN
We report results of serum thyroid hormone and IGF-1 concentrations in 20 children, 1.2 to 13.6 years old, with various degrees of chronic liver dysfunction (CLD), before and after successful orthotopic liver transplantation (OLT). Ten children presented with moderate chronic liver disease (CLD-M) with prothrombin time (PT) > 50% and serum albumin concentration > 3 g/dl; 7 children had severe chronic liver disease (CLD-S) with PT < 50% and serum albumin concentration < 3 g/dl; and 7 children who had received an OLT, who had normal liver function at the time of the study. Four of the latter group were also studied before OLT. Patients with CLD-M had normal mean +/- SD serum levels of total T3 (2.0 +/- 0.7 nmol/l), total T4 (125 +/- 25.9 nmol/l) and fT4 concentrations (16 +/- 2.8 pmol/l). In contrast, children with CLD-S showed a significant decrease in thyroid hormones together with normal basal TSH values (T3 0.8 +/- 0.0 nmol/l; T4 45.6 +/- 19.5 nmol/l; fT4 7.4 +/- 1.1 pmol/l; TSH 3.8 +/- 0.9 mU/l). Patients who received a successful OLT showed mean peripheral thyroid hormone concentrations significantly higher than CLD-S patients (T3 1.7 +/- 0.7 nmol/l, p < 0.005; T4 92.8 +/- 18.2 nmol/l, p < 0.001; fT4 14.5 +/- 3.1 pmol/l, p < 0.001). A significant correlation was found between thyroid hormone levels and PT or serum albumin. In the nine patients with CLD-M and CLD-S in whom serum IGF-1 concentration was measured, values found (mean +/- SD 0.08 +/- 0.05 U/ml) were below the 95% confidence limit of matched controls.
Asunto(s)
Factor I del Crecimiento Similar a la Insulina/metabolismo , Trasplante de Hígado/fisiología , Glándula Tiroides/fisiología , Adolescente , Niño , Preescolar , Femenino , Humanos , Lactante , Hepatopatías/terapia , Masculino , Tiempo de Protrombina , Pruebas de Función de la Tiroides , Hormonas Tiroideas/sangreRESUMEN
Long term feeding a sucrose-rich diet (SRD) to normal Wistar rats led to multiphasic changes in the activity of the pyruvate dehydrogenase complex (PDH), characterized by a significant decrease in PDHa (active form) in the short term on SRD (3 weeks) when compared to control rats fed the standard chow (STD). Although PDHa returned spontaneously to control values in the medium term (6-8 weeks) on SRD, an even more pronounced decrease was recorded when rats were kept long term on the SRD (15 weeks). Low PDHa levels recorded in the short and long term were accompanied by a two fold increase in heart acetyl-CoA concentration and the acetyl-CoA/CoASH ratio. Tissue long-chain acyl-CoA and triacylglycerol levels were also significantly higher in SRD fed rats. Spontaneous normalization of all the above metabolic parameters was observed during the medium term on SRD. Glucose-6-phosphate levels remained within control values during the short and medium term, in contrast to a two fold increase recorded in the long term on SRD. Glycogen concentrations were found moderately elevated only in the long term. Citrate concentrations were slightly increased in the short and greatly in the long term, and the fructose-2,6-bisphosphate/citrate ratio was found significantly decreased only during the long term on SRD. After 3 weeks on SRD, the protal vein Insulin/Glucagon (I/G) molar ratio was three times higher in SRD than STD rats, as opposed to an unchanged I/G ratio found in the long term.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Dieta , Carbohidratos de la Dieta/administración & dosificación , Corazón/efectos de los fármacos , Miocardio/metabolismo , Sacarosa/administración & dosificación , Acilcoenzima A/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Metabolismo de los Hidratos de Carbono , Ingestión de Energía , Ácidos Grasos no Esterificados/sangre , Glucagón/sangre , Insulina/sangre , Metabolismo de los Lípidos , Masculino , Miocardio/enzimología , Complejo Piruvato Deshidrogenasa/metabolismo , Ratas , Ratas Wistar , Triglicéridos/sangreRESUMEN
Deflazacort is an oxazoline compound derived from prednisolone with similar antiinflammatory effects but fewer side effects. We studied changes in kidney function, growth velocity, weight/height ratio, and growth hormone secretion before and a year after substitution of deflazacort for methylprednisone in nine patients aged 9 to 15 years, 4 years after renal transplantation; all were in Tanner pubertal stage 1. Methylprednisone (mean +/- SEM: 0.2 +/- 0.02 mg/kg per day) was replaced by deflazacort (0.3 +/- 0.03 mg/kg per day) for a mean period of 15 months. Serum creatinine and calculated creatinine clearance did not change significantly during deflazacort treatment. Growth velocity increased from 1.5 +/- 0.3 to 3.2 +/- 0.5 cm/yr (p < 0.005) in the nine patients. Weight/height ratio decreased from 28.4% +/- 8.5% to 16% +/- 6.7% (p < 0.005). Cushingoid appearance decreased in all patients. Mean spontaneous growth hormone secretion increased from 2.5 +/- 0.4 to 4.4 +/- 1.2 ng/ml (p < 0.05). Our findings indicate that immunosuppressive treatment with deflazacort is as effective as methylprednisone and is associated with fewer side effects.